Top

Current Treatment Options in Gastroenterology

Published in:

01-12-2017 | Pancreas (V Chandrasekhara, Section Editor)

Diagnosis and Management of Autoimmune Pancreatitis

Authors: Phil A. Hart, MD, Somashekar G. Krishna, MD, MPH, Kazuichi Okazaki, MD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2017

Opinion statement

Although autoimmune pancreatitis is a relatively uncommon pancreatic disorder, it is an important consideration in the differential diagnosis of jaundice and pancreatic masses to avoid unnecessary surgical resection. The clinical diagnosis of autoimmune pancreatitis involves considering multiple pieces of information including the pancreatic imaging, serum IgG4 level, presence of characteristic other involvement, and histologic findings. Unlike other pancreatic disorders, this condition rapidly responds to treatment with steroids. In the more common disease subtype (type 1 autoimmune pancreatitis) disease relapses can occur necessitating the use of maintenance treatment with low-dose steroids, steroid-sparing immunomodulators, or rituximab. This chapter reviews the diagnosis and treatment of the autoimmune pancreatitis subtypes.

Longnecker D. Evolution of the concept of autoimmune pancreatitis and its subtypes Pancreapedia: Exocrine Pancreas Knowledge Base. 2013.

Kawaguchi K, Koike M, Tsuruta K, Okamoto A, Tabata I, Fujita N. Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas. Hum Pathol. 1991;22(4):387–95.CrossRefPubMed

Yoshida K, Toki F, Takeuchi T, Watanabe S, Shiratori K, Hayashi N. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40(7):1561–8.CrossRefPubMed

Chari ST, Singer MV. The problem of classification and staging of chronic pancreatitis. Proposals based on current knowledge of its natural history. Scand J Gastroenterol. 1994;29(10):949–60.CrossRefPubMed

Notohara K, Burgart LJ, Yadav D, Chari S, Smyrk TC. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119–27.CrossRefPubMed

Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139(1):140–148; quiz e12-3. https://doi.org/10.1053/j.gastro.2010.03.054.

Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6. https://doi.org/10.1136/gutjnl-2012-303617.CrossRefPubMed

Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology. 2015;149(1):39–51. https://doi.org/10.1053/j.gastro.2015.03.010.CrossRefPubMed

Chari ST, Kloeppel G, Zhang L, Notohara K, Lerch MM, Shimosegawa T. Histopathologic and clinical subtypes of autoimmune pancreatitis: the Honolulu consensus document. Pancreas. 2010;39(5):549–54. https://doi.org/10.1097/MPA.0b013e3181e4d9e5.CrossRefPubMed

10.

Kamisawa T, Chari ST, Giday SA, Kim MH, Chung JB, Lee KT, et al. Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey. Pancreas. 2011;40(6):809–14. https://doi.org/10.1097/MPA.0b013e3182258a15.CrossRefPubMed

11.

Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–7. https://doi.org/10.1136/gut.2008.172908.CrossRefPubMed

12.

Detlefsen S, Zamboni G, Frulloni L, Feyerabend B, Braun F, Gerke O, et al. Clinical features and relapse rates after surgery in type 1 autoimmune pancreatitis differ from type 2: a study of 114 surgically treated European patients. Pancreatology. 2012;12(3):276–83. https://doi.org/10.1016/j.pan.2012.03.055.CrossRefPubMed

13.

Ryu JK, Chung JB, Park SW, Lee JK, Lee KT, Lee WJ, et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas. 2008;37(4):377–85. https://doi.org/10.1097/MPA.0b013e31817a0914.CrossRefPubMed

14.

Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7(10):1089–96. https://doi.org/10.1016/j.cgh.2009.03.021.CrossRefPubMed

15.

Zamboni G, Luttges J, Capelli P, Frulloni L, Cavallini G, Pederzoli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445(6):552–63. https://doi.org/10.1007/s00428-004-1140-z.CrossRefPubMed

16.

Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675–83. https://doi.org/10.1038/ajg.2014.223.CrossRefPubMedPubMedCentral

17.

Hart PA, Smyrk TC, Chari ST. Lymphoplasmacytic sclerosing pancreatitis without IgG4 tissue infiltration or serum IgG4 elevation: IgG4-related disease without IgG4. Mod Pathol. 2015;28(2):238–47. https://doi.org/10.1038/modpathol.2014.91.CrossRefPubMed

18.

Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352–8. https://doi.org/10.1097/MPA.0b013e3182142fd2.CrossRefPubMed

19.

Hart PA, Chari S. Diagnosis of Autoimmune Pancreatitis. Pancreapedia: Exocrine Pancreas Knowledge Base. 2013.

20.

Hart PA, Levy MJ, Smyrk TC, Takahashi N, Abu Dayyeh BK, Clain JE, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience. Gut. 2016;65(10):1702–9. https://doi.org/10.1136/gutjnl-2015-309275.CrossRefPubMed

21.

•• Okazaki K, Chari ST, Frulloni L, Lerch MM, Kamisawa T, Kawa S, et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology. 2017;17(1):1–6. https://doi.org/10.1016/j.pan.2016.12.003. Consensus recommendations from the International Association of Pancreatology regarding the management of autoimmune pancreatitis. CrossRefPubMed

22.

Buijs J, van Heerde MJ, Rauws EA, de Buy Wenniger LJ, Hansen BE, Biermann K, et al. Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas. 2014;43(2):261–7. https://doi.org/10.1097/MPA.0000000000000044.CrossRefPubMed

23.

Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57(12):1704–12. https://doi.org/10.1136/gut.2008.150979.CrossRefPubMed

24.

Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–70. https://doi.org/10.1007/s00535-014-0945-z.CrossRefPubMed

25.

• Masamune A, Nishimori I, Kikuta K, Tsuji I, Mizuno N, Iiyama T, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut. 2017;66(3):487–94. https://doi.org/10.1136/gutjnl-2016-312049. Randomized clinical trial comparing the use of maintenance steroids versus no maintenance treatment for maintenance of disease remission. CrossRefPubMed

26.

Hart PA, Topazian MD, Witzig TE, Clain JE, Gleeson FC, Klebig RR, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–15. https://doi.org/10.1136/gutjnl-2012-302886.CrossRefPubMed

27.

• Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7. https://doi.org/10.1136/annrheumdis-2014-206605. Open label trial evaluating the efficacy of rituximab for treatment of IgG4-related disease. CrossRefPubMed

28.

Hart PA, Chari ST. Preventing disease relapses in autoimmune pancreatitis with maintenance steroids: are we there yet? Gut. 2017;66(3):394–6.https://doi.org/10.1136/gutjnl-2016-312738.CrossRefPubMed

Title: Diagnosis and Management of Autoimmune Pancreatitis
Authors: Phil A. Hart, MD
Somashekar G. Krishna, MD, MPH
Kazuichi Okazaki, MD
Publication date: 01-12-2017
Publisher: Springer US
Published in: Current Treatment Options in Gastroenterology / Issue 4/2017
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-017-0147-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diagnosis and Management of Autoimmune Pancreatitis

Opinion statement

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 4/2017

Current Management of Benign Epithelial Gastric Polyps

Diabetes and the Pancreatobiliary Diseases

Recent Advances in Pancreatic Cancer Surgery

Management of Inflammatory Fluid Collections and Walled-Off Pancreatic Necrosis

Pancreatic Cancer Screening

Diagnosis and Management of Pancreatic Cystic Neoplasms

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page